BioNTech SE @BioNTech_GroupTomorrow at #SABCS25, Dr. Schmid will present preliminary data from a global multicohort phase 2 trial of a PD-L1 x VEGF-A bispecific antibody plus chemotherapy for 1L/2L+ locally advanced/metastatic TNBC. OriginalDec 9, 2025, 10:00 PM UTC 0 14